The Risk Of Complications From Breast Reconstruction

The Risk Of Complications From Breast Reconstruction.
The overall imperil of complications from core reconstruction after breast removal is only slightly higher for older women than for younger women, a creative study indicates. Researchers looked at data from nearly 41000 women in the United States who had one boob removed between 2005 and 2012. Of those patients, about 11800 also underwent heart of hearts reconstruction. Patients aged 65 and older were less likely to have breast reconstruction than younger women. About 11 percent of older women chose to have the surgery compared to nearly 40 percent of women under 65, the investigation found.

Women who had bosom reconstruction had more complications - such as longer clinic stays and repeat surgeries - than those who did not have breast reconstruction. However, overall complication rates after titty reconstruction were similar. About 7 percent of older women had complications, while slightly more than 5 percent of younger women did. One special case was the risk of blood clot-related complications after heart reconstruction that used a patient's own tissue instead of implants.

Cancer Is A Genetic Disease

Cancer Is A Genetic Disease.
When actress Angelina Jolie went noted about her counteractive double mastectomy, it did not lead to an increased understanding of the genetic risk of bust cancer, researchers say. Although it raised awareness of breast cancer, exposure to Jolie's feature may have resulted in greater confusion about the link between a family history of breast cancer and increased cancer risk, according to the study, published Dec 19, 2013 in the record Genetics in Medicine. Earlier this year, Jolie revealed that she had both breasts removed after culture that she carried a mutation in a gene called BRCA1 that is linked to tit and ovarian cancers.

Women with mutations in that gene and the BRCA2 gene have a five times higher danger of breast cancer and a 10 to 30 times higher imperil of developing ovarian cancer than those without the mutations. For the study, researchers surveyed more than 2500 Americans. About 75 percent were knowledgeable of Jolie's story, the investigators found. But fewer than 10 percent of the respondents could correctly meet questions about the BRCA gene changing that Jolie carries and the typical woman's risk of developing breast cancer.

So "Ms Jolie's salubrity story was prominently featured throughout the media and was a chance to mobilize health communicators and educators to tutor about the nuanced issues around genetic testing, risk and preventive surgery," study govern author Dina Borzekowski, a research professor in the University of Maryland School of Public Health's concern of behavior and community health, said in a university news release. However, it "feels delight in it was a missed opportunity to educate the public about a complex but rare health situation".

Doctors Recommend A New Treatment For Cancer

Doctors Recommend A New Treatment For Cancer.
The remedy Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at tainted risk for the disease, according to a new study Dec 2013. The finding, scheduled for appearance Thursday at the San Antonio Breast Cancer Symposium in Texas, adds count that Arimidex (anastrozole) might be a valuable new preventive option for some women. The study will also be published in the journal The Lancet.

So "Two other antihormone therapies, tamoxifen and raloxifene, are in use by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which determine their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will outstrip to an alternative prevention therapy with fewer string effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, climax of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

About 80 percent of US bust cancer patients have tumors with expensive levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore cast-off to treat postmenopausal women with hormone receptor-positive titty cancer. The study included more than 3800 postmenopausal women at increased endanger for breast cancer due to having two or more blood relatives with breast cancer, having a innate or sister who developed breast cancer before age 50, or having a nourish or sister who had breast cancer in both breasts.

Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy

Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy.
Yearly mammograms for women between the ages of 40 and 50 dramatically bring down the take place that a mastectomy will be life-and-death if they develop breast cancer, a untrained study suggests. British researchers studied the records of 156 women in that seniority range who had been diagnosed with breast cancer between 2003 and 2009, and treated at the London Breast Institute. Of these women, 114 had never had a mammogram and 42 had had at least one mammogram within the at two years, including 16 who had had a mammogram within one year.

About 19 percent of the women who'd been screened within one year had a mastectomy, the deliberate over found, compared with 46 percent of those who had not had a mammogram the premature year. Because annual mammograms allowed tumors to be discovered earlier, breast-sparing surgery was attainable for most of the women, said Dr Nicholas M Perry, the study's premier author. Perry, pilot of the institute, at the Princess Grace Hospital in London, was to present the study findings Wednesday in Chicago at the annual engagement of the Radiological Society of North America.

And "You're talking about lowering the mob of mastectomies by 30 percent. That's 2000 mastectomies in the UK every year, and in the US, that's over 10000 mastectomies saved in a year. The numbers are big and impressive, and chest cancer in minor women is a very big issue". Among all women diagnosed with breast cancer at the London institute during the inquiry period, 40 percent were younger than 50.

According to the American Cancer Society, about 207000 experimental cases of invasive breast cancer will be diagnosed in women in the United States this year. The organization recommends annual mammograms for women 40 and older, but a report in November 2009 from the US Preventive Services Task Force suggested that screenings begin at epoch 50 and be given every other year.

Doctors Recommend A New Complex Cancer Treatment

Doctors Recommend A New Complex Cancer Treatment.
Women with litigious mamma cancer who receive combination targeted therapy with chemotherapy prior to surgery have a minor extent improved chance of staying cancer-free, researchers say. However, the improvement was not statistically significant and the jury is still out on conspiracy treatment, said lead researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels. "I don't fantasize that tomorrow we should switch to a new level of care.

Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other delve into that investigated ways to improve treatment for women with HER2-positive breast cancer. This unfriendly form of cancer is linked to a genetic irregularity. Other researchers reported the following. The targeted narcotize trastuzumab (Herceptin) worked better in HER2-positive breast cancer tumors containing stiff levels of immune cells.

A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery healing option. Overall, the studies were good dope for women with HER2-positive breast cancer, which used to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted remedy drugs. "That tells you these treatments are very, very effective," Piccart-Gebhart said.

Piccart-Gebhart's combo targeted remedial programme bad is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) work better when combined on principal of standard chemotherapy. The trial involved 455 patients with HER2-positive knocker cancer with tumors larger than 2 centimeters. The women were given chemotherapy prior to surgery along with either Herceptin, Tykerb, or a syndicate of the two targeted drugs. They also were treated after surgery with whichever targeted cure they had been receiving.

Piccart-Gebhart reported that 84 percent of the patients who received the combination targeted psychotherapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin. "It's too antediluvian today to say this dual treatment saves more lives. We can't asseverate that on the basis of this trial". The drawbacks of this combination therapy are cost and side effects, Piccart-Gebhart said.

Extract Of Bitter Melon May Slow Breast Cancer

Extract Of Bitter Melon May Slow Breast Cancer.
A accepted nutritional end-piece - extract of bitter melon - may help conserve women from breast cancer, researchers say. Bitter melon is a common vegetable in India, China and South America, and its essence is used in folk remedies for diabetes because of its blood-sugar lowering capabilities, according to the researchers. "When we employed the extract from that melon, we saw that it kills the breast cancer cells," said conduct researcher Ratna Ray, a professor of pathology at Saint Louis University. But their have a job was done in a laboratory, not in humans.

The bitter melon extract killed only the cancer cells, not the healthful breast cells. "We didn't see any death in the normal cells". However, these results are not facts that bitter melon extract prevents or cures breast cancer. "I don't maintain that it will cure cancer. It will probably delay or perhaps have some prevention."

The come in was published online Feb 23 in advance of print publication March 1 in Cancer Research. For the study, Ray's body treated human breast cancer cells with mordant melon extract, which is sold in US health food stores and over the Internet.

The deduce slowed the growth of these breast cancer cells and even killed them, the researchers found. The next imprint is to see if the team can repeat these findings in animals. If so, weak trials might follow.

50 Years Is The Most Dangerous Age For Women

50 Years Is The Most Dangerous Age For Women.
Breast cancer jeopardy in women may be tied to the rank at which their breast-tissue density changes as they age, a revitalized study suggests Dec 2013. Researchers examined 282 breast cancer patients and 317 women without the contagion who underwent both mammography and an automated breast-density test. Breast cancer patients under epoch 50 tended to have greater breast density than healthy women under period 50, the researchers said Tuesday at the annual meeting of the Radiological Society of North America, in Chicago. Overall, the wholesome women also showed a significant, steady decline in their breast density with age.

There was considerably more modulation in the amount of density loss among the breast cancer patients. "The results are interesting, because there would appear to be some cut of different biological density mechanism for normal breasts compared to breasts with cancer, and this appears to be most indisputable for younger women," study senior initiator Nicholas Perry, director of the London Breast Institute in the United Kingdom, said in a friendship news release. "Women under age 50 are most at risk from density-associated breast cancer. Breast cancer in younger women is many a time of a more aggressive type, with larger tumors and a higher jeopardize of recurrence".

Breast density, as determined by mammography, is already known to be a strong and independent risk factor for teat cancer. The American Cancer Society considers women with extremely dense breasts to be at in some measure increased risk of cancer and recommends they talk with their doctors about adding MRI screening to their regular mammograms. "The findings are not likely to diminish the current American Cancer Society guidelines in any way. But it might sum a new facet regarding the possibility of an early mammogram to form an obvious risk factor (breast density), which may then lead to enhanced screening for those women with the densest breasts".

Breast Cancer Treatment Tablets For Osteoporosis

Breast Cancer Treatment Tablets For Osteoporosis.
The bone remedy zoledronic acid (Zometa), considered a potentially heartening weapon against breast cancer recurrence, has flopped in a imaginative study involving more than 3360 patients. The drug, long used to defy bone loss from osteoporosis, did not appear to prevent breast cancer from returning or to boost disease-free survival overall. British researchers presented the pathetic findings Thursday at the San Antonio Breast Cancer Symposium in Texas.

And "As a whole, the ponder is negative," study author Dr Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday scoop discussion on the findings. "There is no overall difference in recurrence rates or survival rates between patients who got the bone narcotize and those who did not, except in older patients, defined as more than five years after menopause".

That was a possible glittering spot in the results. "In that population, there is a benefit". The older women had a 27 percent increase in recurrence and a 29 percent improvement in overall survival over the five-year follow-up, compared to those who didn't get the drug.

And "There was tremendous foresee that this drug approach would be a major leap forward. There have been other trials that suggest this is the case". In one aforementioned study, the use of the drug was linked with a 32 percent reform in survival and lowered recurrence in younger women with breast cancer. Other research has found that shape women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.

Zometa, marketed by Novartis AG, is one of a elegance of drugs used to treat osteoporosis and also to diminish pain when cancers have spread to the bone - in part, by slowing bone erosion caused by the disease. It is given intravenously, while other bisphosphonates such as Actonel, Fosamax or Boniva can be bewitched orally.

Doctors Advise How To Avoid Breast Cancer

Doctors Advise How To Avoid Breast Cancer.
If a sweetheart develops heart cancer, having larger breasts and being sedentary might increase her risk of sinking from the disease, a large, long-term study suggests. Experts have long known that being physically effective reduces the risk of getting breast cancer by about 25 percent. The new study, however, looked at how both bring to bear and breast size might predict survival if breast cancer does develop, said go into researcher Paul Williams, a staff scientist at the Lawrence Berkeley National Laboratory, in Berkeley, California Williams found a nearly 40 percent reduced risk of dying from heart of hearts cancer in physically active women compared to those who didn't meet exercise guidelines.

The meditate on was published online Dec 9, 2013 in the journal PLoS One. For the study, Williams and his set followed nearly 80000 women for 11 years. All were participants in national studies on runners' and walkers' health. About 33000 of the women were walkers and about 46000 were runners. When they entered the study, none of the women had been diagnosed with mamma cancer.

All reported the distances they walked or ran each week, as well as their bra cup greatness and body manipulate and height. During the 11-year follow-up period, 111 mug up participants died from breast cancer. They were in their mid-50s, on average, when they died. Those who met ongoing exercise guidelines were about 42 percent less likely to die of breast cancer compared to those who did not dispose of the guidelines.

These guidelines recommend two and a half hours of moderate activity, an hour and 15 minutes of fit activity or an equivalent combination weekly. The supply of exercise found to be protective against breast cancer was about seven miles of brisk walking or nearly five miles of management each week. "It's not a lot of exercise. "This is more evidence of yet another benefit of exercise.

An Effect Of Hormone Therapy On Breast Cancer

An Effect Of Hormone Therapy On Breast Cancer.
Although several beamy studies in fresh years have linked the use of hormone therapy after menopause with an increased endanger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another mien at three kind studies that investigated hormone therapy and its conceivable health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased hazard of breast cancer amid women who used the combination form of hormone therapy with both estrogen and progesterone.

Women who have had a hysterectomy and use estrogen-only remedial programme also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only psychotherapy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI con was published in July 2002, women dropped hormone remedy in droves.

Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The shrink in breast cancer occurrence started three years before the fall in HRT use commenced, lasted for only one year after the HRT dump commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the covey of new breast cancer cases fell by nearly 7 percent.

In taking a overlook at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria critical to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The proof is not strong enough to say definitively that hormone therapy causes breast cancer. The reading is published in the current issue of the Journal of Family Planning and Reproductive Health Care.

Scientists Have Discovered A New Method Of Detecting Cancer

Scientists Have Discovered A New Method Of Detecting Cancer.
A redone examination marketed as an alternative to a mammogram for breast cancer detection is not an remarkable screening TOOL, US health officials say. With the nipple aspirate test, a tit pump collects fluid from a woman's nipple. The fluid is then examined for unusual and potentially cancerous cells. The test is advertised as easier, more comfortable and less painful than mammograms.

However, there is no document to support claims that the test can detect breast cancer, said Dr David Lerner, a medical dignitary at the US Food and Drug Administration and a breast imaging specialist. "FDA's involve is that the nipple aspirate test is being touted as a standalone tool to screen for and pinpoint breast cancer as an alternative to mammography," Lerner said in an agency news release.

So "Our concern is that women will forgo a mammogram and have this test instead". Skipping a mammogram could put a woman's healthiness and life at risk if breast cancer goes undetected, Lerner warned. He said there is no regulated evidence that the nipple aspirate test, when used on its own, is an effective screening tool for mamma cancer or any other medical condition.

Sustainable Increase In Weight Increases In The Later Stages Of The Life Risk Of Breast Cancer

Sustainable Increase In Weight Increases In The Later Stages Of The Life Risk Of Breast Cancer.
Women who load on the pounds over their lifetime steadily multiply their danger for postmenopausal breast cancer, compared with women who stand by their weight, a new study finds. Earlier studies have linked excess weight with an increased peril for breast cancer in postmenopausal women, but this is one of the few studies that traces the risk as a function of ballast gain over time.

So "Among women who had never used postmenopausal hormone therapy, those who had a body-mass guide (BMI) gain between age 20 and 50 had a doubling of breast cancer risk," said restraint researcher Laura Sue, a cancer research fellow at the US National Cancer Institute. Sue was expected to furnish the findings Tuesday at the American Association for Cancer Research's annual meeting, in Washington DC.

For the study, Sue's group collected data on more than 72000 women who took limited in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. When the reading began, the women were between 55 and 74 years old. Among these women, 3677 had developed a postmenopausal mamma cancer.

Mammogram Warns Against Cancer

Mammogram Warns Against Cancer.
Often-conflicting results from studies on the value of unvaried mammography have only fueled the question about how often women should get a mammogram and at what age they should start. In a new examination of previous research, experts have applied the same statistical yardstick to four large studies and re-examined the results. They found that the benefits are more uniform across the large studies than previously thought. All the studies showed a major reduction in breast cancer deaths with mammography screening.

So "Women should be reassured that mammography is truly effective," said study researcher Robert Smith, senior president of cancer screening for the American Cancer Society. Smith is scheduled to present the findings this week at the 2013 San Antonio Breast Cancer Symposium. The findings also were published in the November originate of the newsletter Breast Cancer Management.

In 2009, the US Preventive Services Task Force (USPSTF), an unallied group of national experts, updated its recommendation on mammography, advising women ancient 50 to 74 to get mammograms every two years, not annually.The group also advised women grey 40 to 49 to talk to their doctors about benefits and harms, and decide on an single basis whether to start screening. Other organizations, including the American Cancer Society, pursue to recommend annual screening mammograms beginning at age 40.

In assessing mammography's benefits and harms, researchers often demeanour at the number of women who must be screened to prevent one death from breast cancer - a gang that has ranged widely among studies. In assessing harms, experts deduce into account the possibility of false positives. Other possible harms include finding a cancer that would not otherwise have been found on screening (and not been difficult in a woman's lifetime) and anxiety associated with additional testing.

Features Of Surgery For Cancer

Features Of Surgery For Cancer.
After chemotherapy, surgery and dispersal to present the original tumor might not benefit women with advanced breast cancer, a new muse about shows in Dec 2013. A minority of women with breast cancer discover they have the virus in its later stages, after it has spread to other parts of the body. These patients typically are started on chemotherapy to serve shrink the cancerous growths and slow the disease's progress. Beyond that, doctors have yearn wondered whether it's also a good idea to treat the original breast tumor with surgery or emanation even though the cancer has taken root in other organs.

And "Our trial did show there's no benefit of doing surgery," said lessons author Dr Rajendra Badwe, head of the surgical breast component at Tata Memorial Hospital in Mumbai, India. It didn't seem to matter if patients were progeny or old, if their cancer was hormone receptor positive or negative, or if they had a few sites of spreading cancer or a lot. Surgery didn't lengthen their lives. The study was scheduled for presentation this week at the annual San Antonio Breast Cancer Symposium, in Texas.

The results aren't shocking, since experiments in animals performed more than 30 years ago suggested that freezing out the elementary tumor only egged on cancer at the supportive sites. But studies in humans have suggested that removing the original cancer in the heart of hearts may increase survival. Those studies aren't thought to be definitive, however, because they looked back only at what happened after women already underwent treatment. One virtuoso not involved in the new study also questioned the electing of patients in the previous research.

So "There's a lot of bias with that because you tend to operate on patients you think might do well to begin with," said Dr Stephanie Bernik, superintendent of surgical oncology at Lenox Hill Hospital in New York City. "We absolutely need more evidence to guide us". To congregate that evidence, researchers randomly assigned 350 women who responded to their initial chemotherapy to one of two courses of treatment. The head group had surgery followed by radiation to remove the primitive breast tumor and lymph nodes under the arms.

Efficiency Of Breast-Feeding On Brain Activity Of The Baby

Efficiency Of Breast-Feeding On Brain Activity Of The Baby.
Breast-feeding is actual for a baby's brain, a late study says in June 2013. Researchers hand-me-down MRI scans to examine brain growth in 133 children ranging in epoch from 10 months to 4 years. By age 2, babies who were breast-fed exclusively for at least three months had greater levels of advance in key parts of the brain than those who were fed rule only or a combination of formula and breast milk. The extra growth was most evident in parts of the sense associated with things such as language, emotional function and thinking skills, according to the study published online May 28 in the roll NeuroImage.

So "We're finding the difference in white context growth is on the order of 20 to 30 percent, comparing the breast-fed and the non-breast-fed kids," reflect on author Sean Deoni, an assistant professor of engineering at Brown University, said in a university statement release. "I think it's astounding that you could have that much difference so early".

African-Americans Began A Thicket To Die From Breast Cancer

African-Americans Began A Thicket To Die From Breast Cancer.
Black chest cancer patients are more no doubt to die than white patients, regardless of the classification of cancer, according to a new study in 2013. This suggests that the lower survival rate amongst black patients is not solely because they are more often diagnosed with less treatable types of breast cancer, the researchers said. For more than six years, the researchers followed nearly 1700 core cancer patients who had been treated for luminal A, luminal B, basal-like or HER2-enriched tit cancer subtypes.

During that period, about 500 of the patients had died, nearly 300 of them from boob cancer. Black patients were nearly twice as likely as creamy patients to have died from breast cancer. The researchers also found that black patients were less likely than fair-skinned patients to be diagnosed with either the luminal A or luminal B breast cancer subtypes.

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a declaration that seems to chip the prevailing wisdom that any form of hormone replacement remedial programme raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone analysis might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone psychotherapy is actually protective" in women who have a low risk for developing mamma tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another appearance at matter from the Women's Health Initiative (WHI) study, a resident trial that has focused on ways to prevent breast and colorectal cancer, as well as nature disease and fracture risk, in postmenopausal women.

The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, far studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.

Two groups were interest of the venture - women who had had hysterectomies and took estrogen unsurpassed as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The claque therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.

In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no erstwhile history of benign knocker disease had a 43 percent reduction breast cancer risk on estrogen; women with no ancestors history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without early hormone use had a 32 percent reduced risk.

Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer

Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer.
In an deed to rally the prognosis of patients battling triple-negative breast cancer, scientists have identified a single biomarker that may eventually allow some to receive a more targeted treatment. Although less uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work.

The disease's big name refers to breast cancers that check-up negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which exacerbate most breast cancer growth. "Triple-negative breast cancers currently shortage therapeutic targets and are managed with conventional chemotherapy," study author Dr Agnieszka K Witkiewicz, an friend professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a scuttlebutt release.

Drinking Green Tea Is Not Associated With Risk Of Breast Cancer

Drinking Green Tea Is Not Associated With Risk Of Breast Cancer.
Although some scrutiny has suggested that drinking leafy tea might help defend women from breast cancer, a new, large Japanese study comes to a different conclusion. "We found no overall friendship between green tea intake and the risk of breast cancer among Japanese women who have habitually under the table green tea," said lead researcher Dr Motoki Iwasaki, from the Epidemiology and Prevention Division at the Research Center for Cancer Prevention and Screening of the National Cancer Center in Tokyo. "Our findings suggest that amateurish tea intake within a usual drinking proclivity is unattractive to reduce the risk of breast cancer".

The report is published in the Oct. 28 online descendant of the journal Breast Cancer Research. For the study, Iwasaki's team controlled data on 53,793 women who were surveyed between 1995 and 1998. As part of the survey, the women were asked how much environmental tea they drank.

This question was asked at the start of the study and again five years later. During the approve survey, the researchers asked about two different types of immature tea, Sencha and Bancha/Genmaicha. Among the women, 12 percent drank less than one cup of wet behind the ears tea a week, while 27 percent drank five or more cups a day, the researchers found. The think over also included women who drank 10 or more cups a day.

Chemotherapy Is One Of The Main Ways To Treat Cancer

Chemotherapy Is One Of The Main Ways To Treat Cancer.
Women fighting an belligerent procedure of breast cancer may benefit from adding non-specified drugs to their chemotherapy regimen, and taking them prior to surgery, new research finds. This pre-surgical cure therapy boosts the likelihood that no cancer cells will be found in breast tissue removed during either mastectomy or lumpectomy, according to two remodelled studies. The approach, called "neoadjuvant" chemotherapy, is being given to an increasing troop of women with what's known as triple-negative breast cancer.

Currently, the approach results in no identifiable cancer cells at mastectomy or lumpectomy in about-one third of patients, experts estimate. In such cases, the endanger of a tumor recurrence becomes lower. "Chemotherapy before surgery does put to in triple-negative bosom cancer. What we want to do is make it work better," said study researcher Dr Hope Rugo.

Rugo is boss of breast oncology and clinical trials education at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. Triple-negative cancers have cells that inadequacy receptors for the hormones estrogen and progesterone. In addition, they don't have an residual of the protein known as HER2 on the stall surfaces.

So, treatments that work on the receptors and drugs that butt HER2 don't work in these cancers. In two new studies, researchers got better results by adding drugs to the burgee chemo regimen prior to surgery. However, both studies are time 2 trials, so more research is needed. Both studies are due to be presented Friday at the annual San Antonio Breast Cancer Symposium.